MaaT Pharma successfully completes a fundraising of 19.2 million euros

MaaT Pharma, based in Lyon, announces the successful finalization of its global offer reaching 19.2 million euros. This operation included the sale of 2,273,704 new ordinary shares at 8 euros per unit, in the context of a reserved offer and a public offer. The majority of funds came from the offer reserved for institutional investors, generating €17.3 million, while individual investors contributed €0.9 million via the PrimaryBid platform.

The capital raised will finance the completion of phase 3 clinical trials for their product MaaT013, essential in the treatment of acute graft-versus-host disease, as well as the development of their portfolio. The company plans to use these funds to expand other clinical trials across Europe and prepare for a phase 3 trial in the United States.

At the same time, Seventure Partners, one of the shareholders, sold 125,000 existing shares for one million euros. MaaT Pharma also uses this financing to cover working capital requirements and the repayment of current debts.